Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Psoriatic Arthritis: later-stage trial registry
22 of 49 indexed Psoriatic Arthritis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #281 of 28,707 conditions by registered trial count.
49 US clinical trials · 22 currently recruiting · #281 of 28,707 conditions by registered trial count
Psoriatic Arthritis: 49 US clinical trials tracked, 22 recruiting.
Psoriatic Arthritis is the subject of 49 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Biopharma SRL, running 5 of these trials.
Enrollment posture brief
Registry condition psoriatic-arthritis
OPEN 22 | RECR 45% | LATE 19 | EARLY 8 | RANK #281 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Cancer (45% recruiting · 621 trials)
Psoriatic Arthritis lists 22 open slots (45% of 49 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Psoriatic Arthritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Psoriatic Arthritis is recruiting above its size-band peers.
22 of 49 indexed trials (44.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Psoriatic Arthritis trials is spread across many organizations.
UCB Biopharma SRL accounts for 5 of 49 trials (10.2%). 28 distinct sponsors appear on at least one study for this condition label.
-
Typical Psoriatic Arthritis enrolment sits around 250 participants.
Median target enrolment is 250 among the 49 trials that report a genuine target (sentinel values excluded). 11 of those (22.4%) plan for fewer than 100 participants.
-
Psoriatic Arthritis research is mostly interventional.
36 interventional and 13 observational studies make up this index (73.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
49 total, page 1 of 1
Psoriatic Arthritis D2P Screening
Jessica Walsh
NCT04110522
Rheumatology Patient Registry and Biorepository
Yale University
NCT04402086
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Takeda
NCT07286058
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
NCT06671483
Psorcast Mobile Study
Sage Bionetworks
NCT05621369
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Takeda
NCT06671496
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
University of Pennsylvania
NCT05908240
Rheumatology Diet Study
University of Central Florida
NCT06339957
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL
NCT07290036
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
A Study of SPY072 in Rheumatic Disease
Spyre Therapeutics
NCT07148414
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
University of California, San Diego
NCT02103361
Creating Health Course Study for People With Rheumatological Conditions
Terry L. Wahls
NCT07180537
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Eli Lilly and Company
NCT06864026
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04751396
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
AbbVie
NCT06865105
Stronger Together Psoriatic Arthritis Wellness Study
Global Healthy Living Foundation
NCT05652608
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Care Arthritis
NCT06454188
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL
NCT06506916
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
University of Pennsylvania
NCT05669833
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
NCT06888193
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
University of California, San Diego
NCT06586281
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL
NCT04009499
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
AbbVie
NCT03675308
OTIS Cimzia Pregnancy Registry
University of California, San Diego
NCT01797224
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Bristol-Myers Squibb
NCT04908189
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB Biopharma SRL
NCT06624228
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Bristol-Myers Squibb
NCT04908202
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
NCT04991116
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company
NCT06588296
Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits
Brigham and Women's Hospital
NCT06004700
Apremilast Pregnancy Exposure Registry
University of California, San Diego
NCT02775500
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
Zimmer Biomet
NCT03626038
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
Brigham and Women's Hospital
NCT05715463
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
Ohio State University
NCT05590247
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
AbbVie
NCT03104400
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Novartis Pharmaceuticals
NCT01392326
Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.
Groupe Hospitalier Pitie-Salpetriere
NCT03119805
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Eli Lilly and Company
NCT02584855
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Amgen
NCT01690299
Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
University of Pennsylvania
NCT03378336
A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
Pfizer
NCT05195814
Impact of Literacy Level on Patient Education and Health Among People With Arthritis
Brigham and Women's Hospital
NCT00023205
Diet Interventions in Psoriatic Arthritis
University of Pennsylvania
NCT04180904
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA
University of Rochester
NCT02413749
Centocor Microarray Study of Patients
University of Rochester
NCT00462072
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study
University of Rochester
NCT01123265
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
AbGenomics B.V Taiwan Branch
NCT02267642
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
UCB Biosciences
NCT02154425
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 16 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Psoriatic Arthritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Psoriatic Arthritis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Psoriatic Arthritis page
49 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Psoriatic Arthritis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UCB Biopharma SRL sponsors the most Psoriatic Arthritis trials on record, review their full trial history before evaluating a specific study. See UCB Biopharma SRL's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Psoriatic Arthritis condition card totals 49 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.